Quadrant Capital Group LLC Purchases 18,764 Shares of Merck & Co., Inc. $MRK

Quadrant Capital Group LLC lifted its holdings in Merck & Co., Inc. (NYSE:MRK) by 27.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 86,654 shares of the company’s stock after purchasing an additional 18,764 shares during the quarter. Quadrant Capital Group LLC’s holdings in Merck & Co., Inc. were worth $7,273,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Brighton Jones LLC increased its holdings in shares of Merck & Co., Inc. by 29.5% in the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock worth $3,808,000 after buying an additional 8,710 shares during the last quarter. Sivia Capital Partners LLC raised its position in shares of Merck & Co., Inc. by 52.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock valued at $910,000 after buying an additional 3,941 shares in the last quarter. Zions Bancorporation National Association UT lifted its holdings in shares of Merck & Co., Inc. by 3.3% in the 2nd quarter. Zions Bancorporation National Association UT now owns 5,591 shares of the company’s stock valued at $443,000 after acquiring an additional 178 shares during the last quarter. ProShare Advisors LLC lifted its holdings in shares of Merck & Co., Inc. by 6.4% in the 2nd quarter. ProShare Advisors LLC now owns 611,733 shares of the company’s stock valued at $48,425,000 after acquiring an additional 37,005 shares during the last quarter. Finally, Allworth Financial LP grew its position in Merck & Co., Inc. by 15.0% in the second quarter. Allworth Financial LP now owns 119,871 shares of the company’s stock worth $9,489,000 after acquiring an additional 15,679 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Late‑stage trial wins for oncology and HIV programs (KEYTRUDA, WELIREG regimens and DOR/ISL HIV therapy) that show improved survival and broadened indications—these readouts raise near‑term revenue potential and long‑term pipeline value. Merck Trial Wins Shape Oncology And HIV Prospects For Investors
• Positive Sentiment: Stock moving higher within the S&P 500 — market‑level strength and rotation into large pharma/defensive names is supporting MRK’s price action. Merck & Co. (NYSE:MRK) Moves Higher Within S&P 500 Index Amid Gains
• Positive Sentiment: Expanding neuroendocrine carcinoma market and other oncology indications — market forecasts to 2036 increase the addressable opportunity for Merck’s targeted therapies, supporting longer‑term growth assumptions for KEYTRUDA and companion assets. Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight
• Neutral Sentiment: Vaccine franchise market reports (Ervebo, M‑M‑R II, Pneumovax 23, Elonva) highlight steady long‑term demand and niche growth opportunities—positive background but unlikely to move near‑term results absent new approvals or major contract wins. Ervebo (Merck & Co) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, 2020-2025, 2025-2030F, 2035F
• Negative Sentiment: Persistent weakness in Gardasil sales (down ~39% in 2025 with weak China demand) — management expects no near‑term rebound, which pressures top‑line growth and investor expectations for vaccine contribution to revenue. Will Weak Gardasil Sales Continue to Weigh on MRK’s Top Line in 2026?
• Negative Sentiment: RBC caution on Winrevair — analyst says the COPD candidate must show a ≥20‑meter improvement in 6‑minute walk to restore confidence; this raises clinical/regulatory uncertainty that could limit upside for that program. Merck’s Winrevair Must Show Walk Distance Improvement to Build Confidence, RBC Says

Merck & Co., Inc. Price Performance

Shares of MRK stock opened at $117.14 on Wednesday. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $125.14. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. The firm has a market capitalization of $289.61 billion, a P/E ratio of 16.09, a P/E/G ratio of 2.27 and a beta of 0.27. The stock has a 50 day moving average price of $114.64 and a 200 day moving average price of $99.14.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $2.01 by $0.03. The company had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.Merck & Co., Inc.’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, sell-side analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be paid a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Monday, March 16th. Merck & Co., Inc.’s payout ratio is currently 46.70%.

Insider Activity

In other news, insider Johannes Jacobus Oosthuizen sold 15,000 shares of the company’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $121.87, for a total value of $1,828,050.00. Following the transaction, the insider directly owned 21,197 shares in the company, valued at approximately $2,583,278.39. This represents a 41.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Jennifer Zachary sold 121,573 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the completion of the transaction, the executive vice president directly owned 68,916 shares in the company, valued at $8,211,341.40. This represents a 63.82% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 320,176 shares of company stock valued at $38,281,735. Insiders own 0.09% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on MRK. Royal Bank Of Canada started coverage on Merck & Co., Inc. in a research note on Wednesday, February 25th. They set an “outperform” rating and a $142.00 price objective on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Merck & Co., Inc. in a research note on Monday, December 29th. Wall Street Zen downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. UBS Group increased their price target on Merck & Co., Inc. from $105.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Finally, Bank of America raised their price target on Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and an average price target of $125.88.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.